Physician profile
Reuben Chen
NPI 1083888069
$1,561.38
in general payments reported to CMS, 2019-2025
32 companies · $24.56 in 2025
The $24.56 reported for 2025 was less than what a typical Physical Medicine & Rehabilitation provider received nationally (typical 2025 total: $138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $489 · 2020: $354 · 2021: $278 · 2022: $154 · 2023: $111 · 2024: $150 · 2025: $24.56.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $286.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $286.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $150.00 | 2024 | Epclusa |
| Biodelivery Sciences International, INC. | $145.44 | 2019-2021 | |
| Allergan, INC. | $137.78 | 2019-2021 | |
| Nevro Corp. | $95.60 | 2019 | |
| Medtronic, INC. | $94.00 | 2022 | |
| Radius Health, INC. | $89.46 | 2022-2023 | Tymlos |
| Medtronic USA, INC. | $82.82 | 2019-2020 | |
| Boston Scientific Corporation | $74.67 | 2019-2023 | |
| Otsuka America Pharmaceutical, INC. | $65.19 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $59.66 | 2019-2020 | |
| Sentynl Therapeutics, INC. | $51.52 | 2019-2020 | |
| Amgen INC. | $48.86 | 2019-2021 | |
| Lundbeck LLC | $46.30 | 2021 | |
| Aesculap, INC. | $42.96 | 2023 | Aesculap, Gav |
| Abbvie INC. | $27.97 | 2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $27.89 | 2021 | |
| Depuy Synthes Sales INC. | $27.37 | 2019 | |
| Avanos Medical | $26.95 | 2019 | |
| Exact Sciences Corporation | $24.56 | 2025 | Cologuard Collection Kit |
| Sunovion Pharmaceuticals INC. | $24.25 | 2020 | |
| Lilly USA, LLC | $24.12 | 2020 | |
| Grt US Holding, INC. | $23.05 | 2019 | |
| Arbor Pharmaceuticals, INC. | $22.57 | 2020 | |
| Alkermes, INC. | $20.24 | 2020 | |
| Sun Pharmaceutical Industries INC. | $20.20 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.04 | 2021 | |
| Bioventus LLC | $17.23 | 2021 | |
| Horizon Therapeutics Plc | $16.00 | 2019 | |
| Alfasigma USA, INC. | $15.57 | 2020 | |
| Augmedics INC. | $13.96 | 2023 | Xvision |
| Assertio Therapeutics, INC. | $13.90 | 2019 | |
| Collegium Pharmaceutical, INC. | $11.25 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reuben Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.